Literature DB >> 12895199

The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.

Sanna Palovaara1, Gunnel Tybring, Kari Laine.   

Abstract

AIMS: To study the effect of an oral contraceptive (OC) formulation containing ethinyloestradiol and levonorgestrel (LNG) (combination OC) or LNG alone on the CYP2C19-mediated hydroxylation of omeprazole in healthy females.
METHODS: This was an open crossover study with three phases. In phase one, 10 healthy females received a single 40-mg dose of omeprazole. Thereafter the subjects received in a random order either 40 micro g ethinyloestradiol and 75 micro g LNG or 60 micro g LNG alone once daily for 10 days. On day 10, 1 h after the last OC dose, subjects received a single 40-mg oral dose of omeprazole. The plasma concentrations of omeprazole, 5'-hydroxyomeprazole and omeprazole sulphone were determined for up to 8 h.
RESULTS: The use of combination OC increased the area under the curve (AUC) of omeprazole by 38% [95% confidence interval (CI) - 3.8, 80; P = 0.040] and caused a 48% increase (95% CI 28, 68) in the AUC ratio of omeprazole/5-hydroxyomeprazole. LNG alone did not effect the 5'-hydroxylation of omeprazole. Neither of the OC preparations seemed to have an inhibitory effect on the formation of omeprazole sulphone by CYP3A4.
CONCLUSIONS: Oral contraceptives containing ethinyloestradiol but not those containing only LNG decrease CYP2C19 activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895199      PMCID: PMC1884281          DOI: 10.1046/j.1365-2125.2003.01868.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  The effect of hormone replacement therapy on CYP3A activity.

Authors:  J C Gorski; Z Wang; B D Haehner-Daniels; S A Wrighton; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

3.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

4.  Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.

Authors:  S Palovaara; K T Kivistö; P Tapanainen; P Manninen; P J Neuvonen; K Laine
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

5.  Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans.

Authors:  M E Krecic-Shepard; C R Barnas; J Slimko; M P Jones; J B Schwartz
Journal:  J Clin Pharmacol       Date:  2000-03       Impact factor: 3.126

6.  Mephenytoin hydroxylase activity in human liver: inhibition by steroids.

Authors:  M Jurima; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Nov-Dec       Impact factor: 3.922

7.  Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives.

Authors:  D R Abernethy; E L Todd
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.

Authors:  K Laine; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

9.  Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics.

Authors:  G P Stoehr; P D Kroboth; R P Juhl; D B Wender; J P Phillips; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

10.  Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.

Authors:  Myong-Jin Kim; Joseph S Bertino; Andrea Gaedigk; Yanhua Zhang; Edward M Sellers; Anne N Nafziger
Journal:  Clin Pharmacol Ther       Date:  2002-08       Impact factor: 6.875

View more
  16 in total

1.  CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Authors:  Margareta Ramsjö; Eleni Aklillu; Lilleba Bohman; Magnus Ingelman-Sundberg; Hyung-Keun Roh; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-05-25       Impact factor: 2.953

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 5.  Sex Differences in Human and Animal Toxicology.

Authors:  Michael Gochfeld
Journal:  Toxicol Pathol       Date:  2016-11-28       Impact factor: 1.902

Review 6.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 7.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 8.  Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.

Authors:  Thomas N Kakuda; Monika Schöller-Gyüre; Richard M W Hoetelmans
Journal:  Clin Pharmacokinet       Date:  2011-01       Impact factor: 6.447

Review 9.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 10.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.